e-therapeutics plc (LON:ETX – Get Free Report)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 9.60 ($0.12) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares trading hands.
e-therapeutics Trading Down 6.7 %
The company has a debt-to-equity ratio of 0.33, a quick ratio of 20.13 and a current ratio of 22.20. The company has a market capitalization of £52.59 million, a price-to-earnings ratio of -450.00 and a beta of 0.46. The firm has a fifty day moving average price of GBX 9 and a 200-day moving average price of GBX 9.58.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Further Reading
- Five stocks we like better than e-therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Intel: Is Now the Time to Be Brave?
- What is a SEC Filing?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Investing In Automotive Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.